Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | F5 | P12259 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 6/20 | 0.35 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3305337 | 0.99 | F10 (0.38) | F10F2F5GRM5CYP46A1 | |
| SCHEMBL1504053 | 0.88 | F10 (0.43) | F10F2F5GRM5CYP46A1 | |
| SCHEMBL2941002 | 0.88 | F10 (0.43) | F10F2F5GRM5CYP46A1 | |
| SCHEMBL6362265 | 0.83 | F10 (0.36) | F10F2F5GRM5CYP46A1 | |
| SCHEMBL6362268 | 0.83 | F10 (0.36) | F10F2F5GRM5CYP46A1 | |
| SCHEMBL3302347 | 0.83 | F10 (0.40) | F10F2F5GRM5CYP46A1 | |
| SCHEMBL3302354 | 0.83 | F10 (0.40) | F10F2F5GRM5CYP46A1 | |
| SCHEMBL13394451 | 0.82 | KCNQ3 (0.35) | F10F2F5NPC1RAB9A | |
| SCHEMBL13394448 | 0.82 | F10 (0.36) | F10F2F5 | |
| Hydrochloric Acid SCHEMBL4261107 | 0.81 | F10 (0.36) | F10F2F5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | DAIICHI PHARMACEUTICAL CO., LTD (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7576135-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7576135-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | F10 152/4885F2 1/4885F5 52/4885 |
| US-20090281074-A1 | DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM | C1R, C9, F2 | F10 127/4885F2 3/4885F5 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.